CONMED CORPORATION (NASDAQ:CNMD) Files An 8-K Results of Operations and Financial Condition
Item 2.02
On April 24, 2019, CONMED Corporation issued a press release announcing financial results for the first quarter of 2019. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under Item 2.02. Results of Operations and Financial Condition and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
| (c) | Exhibits |
The following exhibit is included herewith:
| Exhibit No. | Description of Exhibit |
| 99.1 | Press Release dated April 24, 2019, issued by CONMED Corporation. |
CONMED CORP Exhibit
EX-99.1 2 ex99-1.htm EX-99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 [email protected] CONMED Corporation Announces First Quarter 2019 Financial Results Utica,…
To view the full exhibit click here
About CONMED CORPORATION (NASDAQ:CNMD)
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Its products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Its product lines consist of orthopedic surgery, general surgery and surgical visualization. Its orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. Its general surgery product line offers a range of products in the areas of advanced surgical, endoscopic technologies and critical care. Its surgical visualization product line offers imaging systems for use in minimally invasive orthopedic and general surgery procedures. Its products are distributed domestically directly to over 6,000 hospitals and other healthcare institutions, as well as through medical specialty distributors.
